Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-terminal domain of angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that plays a critical role in the renin-angiotensin system. While ACE has two catalytic domains (N- and C-), the N-domain exhibits distinct substrate specificity, preferentially cleaving peptides like AcSDKP, angiotensin-(1–7), and amyloid β-protein(1–42). Its function extends beyond blood pressure regulation, influencing peptide metabolism in various tissues. Understanding its unique role is important for developing selective inhibitors with potential therapeutic applications in hypertension and neurodegenerative diseases.
Inhibition of angiotensin-converting enzyme activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiotensin-converting enzyme (N-terminal domain) (None).